Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Dr. Ludwig Hantson

Market Cap

NaN undefined USD

Sector

Healthcare

Website

http://www.alexion.com

Last Update

2/22/2024, 12:00:00 PM

Description

Alexion Pharmaceuticals, Inc.

Read More

Overview

Value

51

Growth

31

Health

79

Management

31

Analyst Opinion

86

Total

56

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Has a history of share buybacks
  • Has strong financial health
  • Liked by analysts
  • Low preportion of income is paid as dividend

Risk Factors

  • Earnings have declined recently
  • Disliked by Twitter users
  • Poor earnings and cashflow growth
  • Price-to-earnings ratio of 58.1 is higher than the market average (19.6x)
  • Dividend could be at risk

Market Peers

ALXN

Key Figures

PE Ratio (TTM)

58.12

Margin Of Safety (DCF)

N/A

Revenue Growth (5 Year Average)

4.83%

Ratings Consensus

Strong Buy

Share Buybacks

0.11%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

51

  • Estimated intrinsic-value of N/A is lower than current price ( 182.50 USD)
  • Price-to-earnings ratio of 58.1 is higher than the market average (19.6x)
  • Free-cashflow-yeild of N/A is worse than the market average (4.7%)
  • Margin-of-safety of N/A is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/ANaNNaN

Current Price: 182.5 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

58.12x

Free Cashflow Yeild

N/A

PE/Earnings Growth

3.24

Price/Book

Infinityx

Growth

Growth Score

31

  • Revenue growth has improved this yeara
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of 4.83% is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of -2.38% is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of 10.33% is lower than the market average (12.35%)

Revenue Growth

4.83%

Earnings Growth

-2.38%

Cashflow Growth

10.33%

Health

Health Score

79

  • Has a low level of debt
  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

0.20x

Current Assets/Liabilities

4.52x

Free Cashflow/Total Debt

0.20x

Debt/Capital

0.39x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of N/A is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

N/A

Dividend Growth

0.00%

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

31

  • Has repurchased shares when value is good
  • Has a history of returning value to shareholders through stock buybacks
  • Return-on-capital-employed of 4.62% is lower than the market average (10%)
  • Return-on-equity of 0.00% is lower than the market average (15%)

Average Buybacks/Dilution

0.11%

Recent Buybacks/Dilution

-100.00%

5 Year Price Volitility

15.41%

Return On Assets

0.00%

Return On Capital Employed

4.62%

Return On Equity

0.00%

Return On Free Cashflow

N/A

Return On Investments

0.00%

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

86

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Alexion Pharmaceuticals, Inc.

Currency

USD

Beta

1.259521

Vol Avg

4222993

Ceo

Dr. Ludwig Hantson

Cik

0000899866

Cusip

015351109

Exchange

Nasdaq Global Select

Full Time Employees

3837

Industry

Biotechnology

Sector

Healthcare

Ipo Date

1996-02-01

Address

121 Seaport Blvd

City

Boston

State

MASSACHUSETTS

Country

US

Zip

02210

Phone

14752302596

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies